Friday, May 02, 2008 8:52:07 AM
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the first quarter of 2008 on Wednesday, May 7, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, May 8, 2008 at 8:30 am Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet or by dialing the numbers listed below.
Conference Call details:
Dial-In: (877) 419-6597 (U.S.)
(719) 325-4858 (International)
Passcode: 4845885
Webcast:
To access the call by live webcast, please visit the Investor Relations section of our website at http://www.Avalonrx.com. An archived version of the webcast will be available for 30 days.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon’s lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx® is the company’s proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.
Avalon Pharmaceuticals, Inc.
C. Eric Winzer
Executive Vice President &
Chief Financial Officer
301-556-9900
Fax: (301) 556-9910
info@avalonrx.com
or
Dorland Global Public Relations
Kate Gormley (Media)
215-928-2720
kgormley@dorland.com
or
The Trout Group
Chad Rubin (Investors)
646-378-2947
Source: Business Wire (April 30, 2008 - 8:01 AM EDT)
News by QuoteMedia
www.quotemedia.com
http://biz.yahoo.com/cc/9/93009.html
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM